JP7247106B2 - 内臓痛の治療のための化合物および方法 - Google Patents

内臓痛の治療のための化合物および方法 Download PDF

Info

Publication number
JP7247106B2
JP7247106B2 JP2019561224A JP2019561224A JP7247106B2 JP 7247106 B2 JP7247106 B2 JP 7247106B2 JP 2019561224 A JP2019561224 A JP 2019561224A JP 2019561224 A JP2019561224 A JP 2019561224A JP 7247106 B2 JP7247106 B2 JP 7247106B2
Authority
JP
Japan
Prior art keywords
tetrahydro
diaza
compound
cyclopropa
pentalene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019561224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518649A (ja
JP2020518649A5 (enExample
Inventor
シェリル ジェラルディーン ラッセン,
マルセロ ファビアン ピッチリーロ,
Original Assignee
アリーナ ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ, インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ, インコーポレイテッド
Publication of JP2020518649A publication Critical patent/JP2020518649A/ja
Publication of JP2020518649A5 publication Critical patent/JP2020518649A5/ja
Application granted granted Critical
Publication of JP7247106B2 publication Critical patent/JP7247106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019561224A 2017-05-08 2018-05-08 内臓痛の治療のための化合物および方法 Active JP7247106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762503280P 2017-05-08 2017-05-08
US62/503,280 2017-05-08
PCT/US2018/031688 WO2018208848A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treatment of visceral pain

Publications (3)

Publication Number Publication Date
JP2020518649A JP2020518649A (ja) 2020-06-25
JP2020518649A5 JP2020518649A5 (enExample) 2021-07-26
JP7247106B2 true JP7247106B2 (ja) 2023-03-28

Family

ID=62245468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019561224A Active JP7247106B2 (ja) 2017-05-08 2018-05-08 内臓痛の治療のための化合物および方法

Country Status (13)

Country Link
US (2) US20200078358A1 (enExample)
EP (1) EP3621619B1 (enExample)
JP (1) JP7247106B2 (enExample)
KR (1) KR20200005614A (enExample)
CN (1) CN110709085A (enExample)
AU (1) AU2018266145A1 (enExample)
BR (1) BR112019023214A2 (enExample)
CA (1) CA3062824A1 (enExample)
EA (1) EA201992638A1 (enExample)
ES (1) ES2956059T3 (enExample)
MA (1) MA48625A (enExample)
MX (2) MX2019013311A (enExample)
WO (1) WO2018208848A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019013311A (es) 2017-05-08 2020-08-03 Arena Pharm Inc Compuestos y metodos para el tratamiento del dolor visceral.
WO2023059610A1 (en) * 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
WO2023150648A2 (en) * 2022-02-02 2023-08-10 Makscientific, Llc Pharmaceutical compositions, and preparation and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503161A (ja) 2009-08-28 2013-01-31 アリーナ ファーマシューティカルズ, インコーポレイテッド カンナビノイド受容体モジュレーター
JP2014506602A (ja) 2011-02-25 2014-03-17 アリーナ ファーマシューティカルズ, インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス(カンナビノイド受容体モジュレーター)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605906A (en) 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5971080A (en) 1997-11-26 1999-10-26 Central Sprinkler Corporation Quick response dry pipe sprinkler system
US7308894B2 (en) 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
CN101070316A (zh) 1999-04-28 2007-11-14 萨诺费-阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
IL150302A (en) 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
PL1902034T3 (pl) 2005-06-02 2011-09-30 Glenmark Pharmaceuticals Sa Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
US7597910B2 (en) 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
CA2623803A1 (en) 2005-09-23 2007-03-29 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
SI2081572T1 (sl) 2006-07-04 2010-06-30 Janssen Pharmaceutica Nv Benzimidazolni kanabinoidni agonisti ki nosijo substituirano heterociklično skupino
EA200900403A1 (ru) 2006-09-25 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Соединения, которые модулируют рецептор св2
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
US20080200501A1 (en) 2006-11-03 2008-08-21 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
US20090325936A1 (en) 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
EP2142531B1 (en) 2007-03-30 2015-07-08 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
JP5485148B2 (ja) 2007-06-21 2014-05-07 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
CA2749884C (en) 2009-01-28 2018-01-23 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP6043733B2 (ja) * 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ, インコーポレイテッド カンナビノイド受容体モジュレーター
WO2012116277A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2016085941A1 (en) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
US20180252736A1 (en) 2015-09-01 2018-09-06 Arena Pharmaceuticals, Inc. Cb2 receptor internalization
EA201892280A1 (ru) 2016-04-10 2019-04-30 Арена Фармасьютикалз, Инк. Способы лечения селективными агонистами cb-рецептора
WO2018208847A1 (en) * 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
MX2019013311A (es) 2017-05-08 2020-08-03 Arena Pharm Inc Compuestos y metodos para el tratamiento del dolor visceral.
WO2019056123A1 (en) * 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
US20240165109A1 (en) * 2021-03-02 2024-05-23 Arena Pharmaceuticals, Inc. Methods of Treatment with Selective CB2 Receptor Agonists
WO2023059610A1 (en) * 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503161A (ja) 2009-08-28 2013-01-31 アリーナ ファーマシューティカルズ, インコーポレイテッド カンナビノイド受容体モジュレーター
JP2014506602A (ja) 2011-02-25 2014-03-17 アリーナ ファーマシューティカルズ, インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス(カンナビノイド受容体モジュレーター)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry,2013年07月18日,Vol.56,pp.8224-8256
Journal of Pharmacological Sciences,2008年,Vol.106,pp.219-224
Pharmacological Research,2009年,Vol.60,pp.117-125
クローン病,公益財団法人 難病医学研究財団/難病情報センターホームページ,2010年02月01日,URL:The Wayback Machine - https://web.archive.org/web/20110528112058/http://www.nanbyou.or.jp:80/entry/81, [検索日:2022.05.09]
疼痛,公益社団法人 日本薬学会 薬学用語解説,2009年01月16日,URL:https://www.pharm.or.jp/dictionary/wiki.cgi?疼痛, [検索日:2022.05.09]

Also Published As

Publication number Publication date
ES2956059T3 (es) 2023-12-12
EP3621619C0 (en) 2023-06-28
CA3062824A1 (en) 2018-11-15
EP3621619A1 (en) 2020-03-18
US20230033510A1 (en) 2023-02-02
JP2020518649A (ja) 2020-06-25
US20200078358A1 (en) 2020-03-12
WO2018208848A1 (en) 2018-11-15
MX2019013311A (es) 2020-08-03
BR112019023214A2 (pt) 2020-05-26
MA48625A (fr) 2020-03-18
EA201992638A1 (ru) 2020-03-18
EP3621619B1 (en) 2023-06-28
CN110709085A (zh) 2020-01-17
MX2022008265A (es) 2022-08-04
AU2018266145A1 (en) 2019-11-28
KR20200005614A (ko) 2020-01-15
US12201633B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
CN109970708B (zh) 大麻素受体调节剂
KR101749778B1 (ko) 칸나비노이드 수용체 조절제
US12201633B2 (en) Compounds and methods for treatment of visceral pain
WO2018208847A1 (en) Compounds and methods for treatment of pain from inflammatory bowel disease
HK40011011A (en) Cannabinoid receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210507

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230120

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230315

R150 Certificate of patent or registration of utility model

Ref document number: 7247106

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150